Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
Algernon Pharmaceuticals (OTCQB: AGNPF) has received a notice of allowance from the European Patent Office for its lead chronic kidney disease drug NP-251 (Repirinast). The patent covers the use of Repirinast, alone or combined with telmisartan, for treating renal fibrosis or kidney disease.
The base claims will be valid through 2038, with potential additional protection through adjustments or extensions. The company has already secured patent allowances in the U.S., Japan, and China, with a pending application in Canada.
Key highlights:
- Repirinast reduced fibrosis by 51% with statistical significance in a mouse model
- Showed additive benefits when combined with telmisartan
- Company granted 50,000 restricted share units and 50,000 stock options to consultants, exercisable at $0.09 for five years
Algernon Pharmaceuticals (OTCQB: AGNPF) ha ricevuto un avviso di concessione dall'Ufficio Europeo dei Brevetti per il suo principale farmaco per la malattia renale cronica NP-251 (Repirinast). Il brevetto copre l'uso di Repirinast, da solo o in combinazione con telmisartan, per il trattamento della fibrosi renale o della malattia renale.
Le rivendicazioni di base saranno valide fino al 2038, con la possibilità di ulteriore protezione tramite aggiustamenti o proroghe. L'azienda ha già ottenuto concessioni di brevetto negli Stati Uniti, in Giappone e in Cina, con una domanda in attesa in Canada.
Punti salienti:
- Repirinast ha ridotto la fibrosi del 51% con significatività statistica in un modello murino
- Ha mostrato benefici additivi quando combinato con telmisartan
- L'azienda ha concesso 50.000 unità di azioni riservate e 50.000 opzioni su azioni ai consulenti, esercitabili a $0.09 per cinque anni
Algernon Pharmaceuticals (OTCQB: AGNPF) ha recibido un aviso de concesión de la Oficina Europea de Patentes para su medicamento principal para la enfermedad renal crónica NP-251 (Repirinast). La patente cubre el uso de Repirinast, solo o combinado con telmisartán, para tratar la fibrosis renal o la enfermedad renal.
Las reivindicaciones básicas serán válidas hasta 2038, con la posibilidad de protección adicional mediante ajustes o extensiones. La empresa ya ha asegurado concesiones de patentes en EE. UU., Japón y China, con una solicitud pendiente en Canadá.
Aspectos destacados:
- Repirinast redujo la fibrosis en un 51% con significancia estadística en un modelo de ratón
- Mostró beneficios aditivos cuando se combina con telmisartán
- La empresa otorgó 50,000 unidades de acciones restringidas y 50,000 opciones sobre acciones a consultores, ejercitables a $0.09 durante cinco años
알제르논 제약 회사 (OTCQB: AGNPF)는 만성 신장 질환 약물 NP-251 (레피리나스트)에 대해 유럽 특허청으로부터 허가 통지를 받았습니다. 이 특허는 레피리나스트를 단독으로 또는 텔미사르탄과 결합하여 신장 섬유증 또는 신장 질환을 치료하는 데 사용되는 것을 포함합니다.
기본 청구는 2038년까지 유효하며, 조정 또는 연장을 통해 추가 보호가 가능할 수 있습니다. 이 회사는 이미 미국, 일본 및 중국에서 특허 허가를 받았으며, 캐나다에서는 신청이 진행 중입니다.
주요 하이라이트:
- 레피리나스트는 생쥐 모델에서 51%의 섬유증을 통계적으로 유의미하게 감소시켰습니다
- 텔미사르탄과 결합했을 때 추가적인 이점을 보였습니다
- 회사는 컨설턴트에게 50,000개의 제한 주식 단위와 50,000개의 주식 옵션을 부여했으며, 이는 5년 동안 $0.09에 행사 가능합니다
Algernon Pharmaceuticals (OTCQB: AGNPF) a reçu un avis d'autorisation de l'Office Européen des Brevets pour son principal médicament contre la maladie rénale chronique NP-251 (Repirinast). Le brevet couvre l'utilisation de Repirinast, seul ou en combinaison avec le télmisartan, pour traiter la fibrose rénale ou la maladie rénale.
Les revendications de base seront valides jusqu'en 2038, avec une protection supplémentaire potentielle par le biais d'ajustements ou d'extensions. L'entreprise a déjà obtenu des autorisations de brevet aux États-Unis, au Japon et en Chine, avec une demande en attente au Canada.
Points clés :
- Repirinast a réduit la fibrose de 51% avec une signification statistique dans un modèle murin
- A montré des bénéfices additifs lorsqu'il est combiné avec le télmisartan
- L'entreprise a accordé 50 000 unités d'actions restreintes et 50 000 options d'actions à des consultants, exerçables à 0,09 $ pendant cinq ans
Algernon Pharmaceuticals (OTCQB: AGNPF) hat eine Genehmigungsmitteilung vom Europäischen Patentamt für sein führendes Medikament gegen chronische Nierenerkrankungen NP-251 (Repirinast) erhalten. Das Patent umfasst die Verwendung von Repirinast, allein oder in Kombination mit Telmisartan, zur Behandlung von Nierenfibrose oder Nierenerkrankungen.
Die grundlegenden Ansprüche sind bis 2038 gültig, mit der Möglichkeit zusätzlicher Schutzmaßnahmen durch Anpassungen oder Verlängerungen. Das Unternehmen hat bereits Patenterteilungen in den USA, Japan und China gesichert, mit einem laufenden Antrag in Kanada.
Wichtige Höhepunkte:
- Repirinast reduzierte die Fibrose um 51% mit statistischer Signifikanz in einem Mausmodell
- Zeigte additive Vorteile in Kombination mit Telmisartan
- Das Unternehmen gewährte 50.000 beschränkte Aktienanteile und 50.000 Aktienoptionen an Berater, die für fünf Jahre zu einem Preis von 0,09 $ ausgeübt werden können
- Secured European patent protection for Repirinast through 2038
- Demonstrated 51% reduction in fibrosis with statistical significance
- Patent protection already secured in major markets: US, Japan, and China
- Showed additive benefits when combined with existing treatment (telmisartan)
- Patent still pending in Canadian market
- Stock options and RSUs grant may lead to minor dilution
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the European Patent Office (EPO) for patent application 19827430.0 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast).
The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
The Company has previously announced the allowance of this patent application in the U.S., Japan and China. The patent is currently pending in Canada.
Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms.
“This is our first patent issued by the EPO and marks another key milestone for the Company,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
The Company also announces a grant of 50,000 restricted share units (each, an "RSU") and 50,000 stock options to consultants of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The stock options are exercisable at
The RSUs and stock options are subject to approval by regulatory authorities.
About NP-251 (Repirinast)
Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name RometTM for the treatment of Asthma. RometTM was marketed for over 25 years in Japan. Mitsubishi discontinued manufacturing and sales of the drug in 2013. Accordingly, Algernon has retained Zhejiang Ausun Pharmaceutical in Zhejiang, China to manufacture a cGMP Repirinast supply.
Mast cells are recruited to sites of cellular damage, and degranulation of mast cells leads to release of a myriad of proinflammatory chemical mediators which lead to tissue damage in a self-propagating cascade. NP-251 binds to receptors on mast cells and prevents their degranulation, which the Company believes could help prevent fibrosis in multiple organ classes including the kidneys.
About Algernon Pharmaceuticals
Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury.
Visit www.algernonpharmaceuticals.com for more information.
Visit www.algernonneuroscience.com for more information.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the significance of Algernon's (AGNPF) European patent allowance for Repirinast?
How effective was Repirinast in Algernon's (AGNPF) kidney disease trials?
What is the duration of Algernon's (AGNPF) European patent protection for Repirinast?
What stock compensation did Algernon (AGNPF) grant to consultants in 2025?
